Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 9
2007 9
2008 21
2009 29
2010 31
2011 48
2012 74
2013 81
2014 71
2015 105
2016 121
2017 114
2018 102
2019 91
2020 88
2021 97
2022 81
2023 73
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

1,123 results

Results by year

Filters applied: . Clear all
Page 1
Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy.
Shan S, Chen J, Sun Y, Wang Y, Xia B, Tan H, Pan C, Gu G, Zhong J, Qing G, Zhang Y, Wang J, Wang Y, Wang Y, Zuo P, Xu C, Li F, Guo W, Xu L, Chen M, Fan Y, Zhang L, Liang XJ. Shan S, et al. Adv Sci (Weinh). 2022 Jul;9(21):e2200353. doi: 10.1002/advs.202200353. Epub 2022 May 18. Adv Sci (Weinh). 2022. PMID: 35585670 Free PMC article.
In this paper, a nano drug delivery system based on functionalized macrophage exosomes with panobinostat and PPM1D-siRNA for targeted therapy of DIPG with PPM1D mutation is prepared. ...In vivo and in vitro experimental results show that the nano drug delivery system can d …
In this paper, a nano drug delivery system based on functionalized macrophage exosomes with panobinostat and PPM1D-siRNA for targeted …
Panobinostat for the management of multiple myeloma.
Sivaraj D, Green MM, Gasparetto C. Sivaraj D, et al. Future Oncol. 2017 Mar;13(6):477-488. doi: 10.2217/fon-2016-0329. Epub 2016 Oct 25. Future Oncol. 2017. PMID: 27776419 Review.
For this reason newer therapeutic agents are needed to combat this malignancy. Panobinostat is a pan-deacetylase inhibitor that impedes protein destruction by disturbing the enzymatic activity of deacetylases. It was US FDA approved in February 2015 for the management of r …
For this reason newer therapeutic agents are needed to combat this malignancy. Panobinostat is a pan-deacetylase inhibitor that imped …
Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
Berdeja JG, Laubach JP, Richter J, Stricker S, Spencer A, Richardson PG, Chari A. Berdeja JG, et al. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):752-765. doi: 10.1016/j.clml.2021.06.020. Epub 2021 Jun 26. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34340951 Review.
Panobinostat is a promising HDACi for the treatment of multiple myeloma. Here, we present a comprehensive review of preclinical and clinical studies of panobinostat....
Panobinostat is a promising HDACi for the treatment of multiple myeloma. Here, we present a comprehensive review of preclinical and c …
Panobinostat: first global approval.
Garnock-Jones KP. Garnock-Jones KP. Drugs. 2015 Apr;75(6):695-704. doi: 10.1007/s40265-015-0388-8. Drugs. 2015. PMID: 25837990 Review.
Panobinostat is in various stages of clinical development worldwide for a range of haematological and solid tumours. This article summarizes the milestones in the development of panobinostat leading to this first approval for multiple myeloma....
Panobinostat is in various stages of clinical development worldwide for a range of haematological and solid tumours. This article sum …
Panobinostat for the Treatment of Multiple Myeloma.
Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Laubach JP, et al. Clin Cancer Res. 2015 Nov 1;21(21):4767-73. doi: 10.1158/1078-0432.CCR-15-0530. Epub 2015 Sep 11. Clin Cancer Res. 2015. PMID: 26362997 Review.
Panobinostat is a potent oral deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation. ...Additional ongoing trials are evaluating panobinostat in combination with other partners in the relapsed/refractory and …
Panobinostat is a potent oral deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein de …
panobinostat (FARYDAK). Multiple myeloma: too toxic!
[No authors listed] [No authors listed] Prescrire Int. 2016 Nov;25(176):257-259. Prescrire Int. 2016. PMID: 30715819 Review.
Panobinostat did not prolong survival. The median time to myeloma progression, relapse, or death was prolonged by about 3 months with the panobinostat-containing combination, and by a median of about 8 months in the subgroup of patients who had received at least two …
Panobinostat did not prolong survival. The median time to myeloma progression, relapse, or death was prolonged by about 3 months with …
Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.
Van Veggel M, Westerman E, Hamberg P. Van Veggel M, et al. Clin Pharmacokinet. 2018 Jan;57(1):21-29. doi: 10.1007/s40262-017-0565-x. Clin Pharmacokinet. 2018. PMID: 28667459 Review.
The absolute bioavailability of panobinostat is 21.4%, and it is moderately bound to plasma proteins. ...Panobinostat itself is a CYP2D6 inhibitor, which influences the plasma levels of the CYP2D6 substrate dexamethasone. ...
The absolute bioavailability of panobinostat is 21.4%, and it is moderately bound to plasma proteins. ...Panobinostat itself i …
Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F, Voso MT, Hohaus S, Gentile M, Vigna E, Recchia AG, Iovino L, Benedetti E, Lo-Coco F, Galimberti S. Morabito F, et al. Expert Opin Investig Drugs. 2016 Sep;25(9):1117-31. doi: 10.1080/13543784.2016.1216971. Epub 2016 Aug 8. Expert Opin Investig Drugs. 2016. PMID: 27485472 Review.
AREAS COVERED: The review discusses the underlying mechanisms leading to disruption of lysine acetyltransferases (KAT or HAT)/deacetylase (KDAC or HDAC) balance and the rationale for using the HDACi panobinostat (LBH-589) in AML. EXPERT OPINION: Although panobinostat …
AREAS COVERED: The review discusses the underlying mechanisms leading to disruption of lysine acetyltransferases (KAT or HAT)/deacetylase (K …
Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.
Greig SL. Greig SL. Target Oncol. 2016 Feb;11(1):107-14. doi: 10.1007/s11523-015-0413-6. Target Oncol. 2016. PMID: 26826025 Review.
Panobinostat plus bortezomib and dexamethasone had a generally manageable tolerability profile, with the most frequent grade 3-4 adverse events being myelosuppression, diarrhoea, asthenia or fatigue, peripheral neuropathy and pneumonia. Thus, panobinostat, in combin …
Panobinostat plus bortezomib and dexamethasone had a generally manageable tolerability profile, with the most frequent grade 3-4 adve …
Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas.
Jane EP, Reslink MC, Gatesman TA, Halbert ME, Miller TA, Golbourn BJ, Casillo SM, Mullett SJ, Wendell SG, Obodo U, Mohanakrishnan D, Dange R, Michealraj A, Brenner C, Agnihotri S, Premkumar DR, Pollack IF. Jane EP, et al. Mol Oncol. 2023 Sep;17(9):1821-1843. doi: 10.1002/1878-0261.13427. Epub 2023 May 12. Mol Oncol. 2023. PMID: 37014128 Free PMC article.
In previous studies, we demonstrated that panobinostat, a histone deacetylase inhibitor, and bortezomib, a proteasomal inhibitor, displayed synergistic therapeutic activity against pediatric and adult high-grade gliomas. ...Here, in this study, we aimed to investigate the …
In previous studies, we demonstrated that panobinostat, a histone deacetylase inhibitor, and bortezomib, a proteasomal inhibitor, dis …
1,123 results

Searches related to "panobinostat"